| Filed |
Name |
|
Company |
Pur. £ |
Cur. £ |
P/L % |
MPV* |
|
Apr '12
|
Lord Glendonbrook
|
|
Astrazeneca / LSE:AZN.L |
£2,666.50
|
£13,154.00
|
393.31%
|
£345,314.08
|
|
Apr '10
|
Baroness Noakes
|
|
Astrazeneca / LSE:AZN.L |
£2,938.00
|
£13,154.00
|
347.72%
|
£313,403.68
|
|
Mar '14
|
Viscount Eccles
|
|
Astrazeneca / LSE:AZN.L |
£3,876.50
|
£15,316.00
|
295.10%
|
£276,569.07**
|
|
Feb '11
|
Lord Wasserman
|
|
Johnson & Johnson / NYQ:JNJ |
£60.93
|
£228.39
|
274.84%
|
£262,387.99
|
|
Dec '16
|
Lord Burns
|
|
Astrazeneca / LSE:AZN.L |
£4,116.00
|
£13,154.00
|
219.58%
|
£223,707.48
|
|
Jan '13
|
Lord Sassoon
|
|
Johnson & Johnson / NYQ:JNJ |
£72.69
|
£228.39
|
214.20%
|
£219,938.09
|
|
May '11
|
Lord Glendonbrook
|
|
Novartis / NYQ:NVS |
£54.04
|
£147.08
|
172.16%
|
£190,513.84
|
|
May '18
|
Lord Grabiner
|
|
Astrazeneca / LSE:AZN.L |
£5,417.00
|
£13,154.00
|
142.83%
|
£169,979.69
|
|
Apr '17
|
Lord Donoughue
|
|
Novartis / NYQ:NVS |
£66.05
|
£147.08
|
122.69%
|
£155,879.66
|
|
Sep '16
|
Lord Gadhia
|
|
Astrazeneca / LSE:AZN.L |
£5,099.00
|
£10,024.00
|
96.59%
|
£137,611.30**
|
|
Jul '16
|
Lord Lloyd-Webber
|
|
Johnson & Johnson / NYQ:JNJ |
£122.64
|
£228.39
|
86.23%
|
£130,359.59
|
|
Feb '21
|
Lord Etherton
|
|
Astrazeneca / LSE:AZN.L |
£7,422.00
|
£13,154.00
|
77.23%
|
£124,060.90
|
|
Nov '23
|
Lord Mance
|
|
Eli Lilly Co / VIE:LLYC.VI |
£557.00
|
£951.70
|
70.86%
|
£119,603.23
|
|
Apr '21
|
Baroness Deech
|
|
Novartis / NYQ:NVS |
£88.38
|
£147.08
|
66.42%
|
£116,492.42
|
|
Jun '21
|
Lord Morse
|
|
Astrazeneca / LSE:AZN.L |
£8,005.00
|
£13,154.00
|
64.32%
|
£115,025.61
|
|
Aug '14
|
Lord Carter of Coles
|
|
Johnson & Johnson / NYQ:JNJ |
£100.16
|
£161.55
|
61.29%
|
£112,904.35**
|
|
Apr '24
|
Lord Mendoza
|
|
Eli Lilly / NYQ:LLY |
£731.33
|
£1,098.57
|
50.22%
|
£105,150.75
|
|
Mar '25
|
Lord Fink
|
|
Johnson & Johnson / NYQ:JNJ |
£161.72
|
£228.39
|
41.23%
|
£98,857.90
|
|
May '23
|
Lord Fink
|
|
Johnson & Johnson / NYQ:JNJ |
£165.03
|
£228.39
|
38.39%
|
£96,875.11
|
|
May '25
|
Lord Hayward
|
|
Glaxosmithkline / NYQ:GSK |
£37.37
|
£50.67
|
35.59%
|
£94,913.03
|
|
Dec '16
|
Lord Burns
|
|
Glaxosmithkline / NYQ:GSK |
£37.39
|
£50.67
|
35.52%
|
£94,862.26
|
|
May '24
|
Lord Goldsmith
|
|
Abbvie / NYQ:ABBV |
£160.81
|
£216.49
|
34.62%
|
£94,237.30
|
|
May '20
|
Lord Deighton
|
|
Astrazeneca / LSE:AZN.L |
£8,361.00
|
£11,236.00
|
34.39%
|
£94,070.09**
|
|
May '11
|
Lord Glendonbrook
|
|
Pfizer / NYQ:PFE |
£19.54
|
£25.21
|
28.99%
|
£90,290.96
|
|
Apr '10
|
Lord Levene of Portsoken
|
|
Glaxosmithkline / NYQ:GSK |
£39.38
|
£50.67
|
28.67%
|
£90,068.56
|
|
Nov '23
|
Lord Mance
|
|
Astrazeneca / LSE:AZN.L |
£10,230.00
|
£13,154.00
|
28.58%
|
£90,007.82
|
|
Apr '10
|
Baroness Noakes
|
|
Glaxosmithkline / NYQ:GSK |
£39.49
|
£50.67
|
28.31%
|
£89,817.67
|
|
Jan '24
|
Lord Fink
|
|
Roche / EBS:ROG.SW |
£251.85
|
£321.70
|
27.73%
|
£89,414.34
|
|
Apr '17
|
Lord Leigh of Hurley
|
|
Roche / EBS:ROG.SW |
£255.80
|
£321.70
|
25.76%
|
£88,033.62
|
|
Mar '17
|
Lord Lloyd-Webber
|
|
Glaxosmithkline / NYQ:GSK |
£42.31
|
£50.67
|
19.76%
|
£83,831.24
|
|
May '11
|
Lord Glendonbrook
|
|
Glaxosmithkline / NYQ:GSK |
£42.78
|
£50.67
|
18.44%
|
£82,910.24
|
|
Aug '17
|
Lord Sterling of Plaistow
|
|
Johnson & Johnson / NYQ:JNJ |
£133.45
|
£157.98
|
18.38%
|
£82,866.99**
|
|
May '24
|
Lord Balfe
|
|
Glaxosmithkline / NYQ:GSK |
£44.02
|
£50.67
|
15.11%
|
£80,574.74
|
|
Apr '26
|
Lord Grabiner
|
|
Eli Lilly / NYQ:LLY |
£955.19
|
£1,098.57
|
15.01%
|
£80,507.43
|
|
Jan '13
|
Lord Sassoon
|
|
Glaxosmithkline / NYQ:GSK |
£44.75
|
£50.67
|
13.23%
|
£79,260.33
|
|
Apr '23
|
Lord Grabiner
|
|
Novartis / NYQ:NVS |
£95.80
|
£107.52
|
12.23%
|
£78,563.67**
|
|
May '23
|
Lord Fink
|
|
Astrazeneca / LSE:AZN.L |
£11,774.00
|
£13,154.00
|
11.72%
|
£78,204.52
|
|
Apr '21
|
Lord Farmer
|
|
Glaxosmithkline / NYQ:GSK |
£36.65
|
£40.88
|
11.54%
|
£78,079.12**
|
|
May '23
|
Lord Londesborough
|
|
Astrazeneca / LSE:AZN.L |
£11,924.00
|
£13,154.00
|
10.32%
|
£77,220.73
|
|
Apr '24
|
Lord Balfe
|
|
Astrazeneca / LSE:AZN.L |
£12,024.00
|
£13,154.00
|
9.40%
|
£76,578.51
|
|
Oct '20
|
Lord Taverne
|
|
Glaxosmithkline / NYQ:GSK |
£37.57
|
£40.95
|
9.00%
|
£76,297.58**
|
|
May '24
|
Lord Goldsmith
|
|
Astrazeneca / LSE:AZN.L |
£12,156.00
|
£13,154.00
|
8.21%
|
£75,746.96
|
|
Mar '25
|
Lord Fink
|
|
Roche / EBS:ROG.SW |
£303.00
|
£321.70
|
6.17%
|
£74,320.13
|
|
Mar '14
|
Baroness Eccles of Moulton
|
|
Glaxosmithkline / NYQ:GSK |
£53.43
|
£56.69
|
6.10%
|
£74,271.01**
|
|
May '23
|
Lord Leitch
|
|
Astrazeneca / LSE:AZN.L |
£11,820.00
|
£12,340.00
|
4.40%
|
£73,079.53**
|
|
Nov '25
|
Lord Green of Hurstpierpoint
|
|
Roche / EBS:ROG.SW |
£309.00
|
£321.70
|
4.11%
|
£72,877.03
|
|
Apr '21
|
Lord Grabiner
|
|
Roche / EBS:ROG.SW |
£309.65
|
£321.70
|
3.89%
|
£72,724.05
|
|
Feb '25
|
Lord Green of Hurstpierpoint
|
|
Roche / EBS:ROG.SW |
£285.70
|
£272.40
|
-4.66%
|
£66,741.33**
|
|
Jan '20
|
Lord Gadhia
|
|
Glaxosmithkline / NYQ:GSK |
£46.50
|
£40.95
|
-11.94%
|
£61,645.16**
|
|
Feb '16
|
Lord Lloyd-Webber
|
|
Pfizer / NYQ:PFE |
£29.02
|
£25.21
|
-13.14%
|
£60,803.98
|
|
Apr '22
|
Lord Cromwell
|
|
Johnson & Johnson / NYQ:JNJ |
£179.90
|
£154.37
|
-14.19%
|
£60,066.15**
|
|
May '23
|
Lord Reay
|
|
Sanofi / NMS:SNY |
£55.11
|
£47.22
|
-14.32%
|
£59,978.23**
|
|
Aug '16
|
Lord Lloyd-Webber
|
|
Eli Lilly / NYQ:LLY |
£80.55
|
£67.15
|
-16.64%
|
£58,355.06**
|
|
Aug '20
|
Lord Reay
|
|
Roche / EBS:ROG.SW |
£315.05
|
£249.80
|
-20.71%
|
£55,502.30**
|
|
Jul '18
|
Lord Glendonbrook
|
|
Bayer / GER:BAYN.DE |
£95.26
|
£37.15
|
-61.00%
|
£27,298.97
|
* Minimum Potential Value based on £70,000.00 invested at time of declaration.
** Interest ceased/exited on filed date.